Sirnaomics-B (Stock Code: 02257) Announces Partial Completion of Subscription and Terminates Remaining Shares

Bulletin Express03-08

Sirnaomics Ltd. reported that on March 7, 2026, 2.50 million new shares were issued at HK$12.00 each under Subscription Agreement A, resulting in a partial completion of the transaction. By mutual agreement on the same date, the subscription for the remaining 9.07 million shares was terminated without further obligations.

After this partial completion, the total number of shares increased from 107.22 million to 109.72 million. Following the issuance, the stake of the largest shareholder, Quarmaceutical Limited (wholly owned by Chairman and Executive Director Dr. Poon Hung Fai), changed from 16.44% to 16.07%. The shareholding of Dr. Yang Lu decreased from 5.02% to 4.90%, while Subscriber A owned 2.28% after the transaction.

Gross proceeds from the subscriptions amounted to HK$54.70 million, with net proceeds of HK$53.10 million. Of those net proceeds, HK$25.00 million (47.10%) is allocated to the development and commercialization of STP705, HK$3.50 million (6.60%) to STP122G, and HK$16.60 million (31.30%) to other drug candidates including STP707, STP125G, and STP144G. An additional HK$4.00 million (7.50%) is earmarked for business development activities, while another HK$4.00 million (7.50%) is reserved for general corporate and working capital purposes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158230419?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-08 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158230419","market":"us","top_or_hot":-1,"title":"Sirnaomics-B (Stock Code: 02257) Announces Partial Completion of Subscription and Terminates Remaining Shares","media":"Bulletin Express","content":"<p>Sirnaomics Ltd. reported that on March 7, 2026, 2.50 million new shares were issued at HK$12.00 each under Subscription Agreement A, resulting in a partial completion of the transaction. By mutual agreement on the same date, the subscription for the remaining 9.07 million shares was terminated without further obligations.</p>\n<p>After this partial completion, the total number of shares increased from 107.22 million to 109.72 million. Following the issuance, the stake of the largest shareholder, Quarmaceutical Limited (wholly owned by Chairman and Executive Director Dr. Poon Hung Fai), changed from 16.44% to 16.07%. The shareholding of Dr. Yang Lu decreased from 5.02% to 4.90%, while Subscriber A owned 2.28% after the transaction.</p>\n<p>Gross proceeds from the subscriptions amounted to HK$54.70 million, with net proceeds of HK$53.10 million. Of those net proceeds, HK$25.00 million (47.10%) is allocated to the development and commercialization of STP705, HK$3.50 million (6.60%) to STP122G, and HK$16.60 million (31.30%) to other drug candidates including STP707, STP125G, and STP144G. An additional HK$4.00 million (7.50%) is earmarked for business development activities, while another HK$4.00 million (7.50%) is reserved for general corporate and working capital purposes.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sirnaomics-B (Stock Code: 02257) Announces Partial Completion of Subscription and Terminates Remaining Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSirnaomics-B (Stock Code: 02257) Announces Partial Completion of Subscription and Terminates Remaining Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-08 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sirnaomics Ltd. reported that on March 7, 2026, 2.50 million new shares were issued at HK$12.00 each under Subscription Agreement A, resulting in a partial completion of the transaction. By mutual agreement on the same date, the subscription for the remaining 9.07 million shares was terminated without further obligations.</p>\n<p>After this partial completion, the total number of shares increased from 107.22 million to 109.72 million. Following the issuance, the stake of the largest shareholder, Quarmaceutical Limited (wholly owned by Chairman and Executive Director Dr. Poon Hung Fai), changed from 16.44% to 16.07%. The shareholding of Dr. Yang Lu decreased from 5.02% to 4.90%, while Subscriber A owned 2.28% after the transaction.</p>\n<p>Gross proceeds from the subscriptions amounted to HK$54.70 million, with net proceeds of HK$53.10 million. Of those net proceeds, HK$25.00 million (47.10%) is allocated to the development and commercialization of STP705, HK$3.50 million (6.60%) to STP122G, and HK$16.60 million (31.30%) to other drug candidates including STP707, STP125G, and STP144G. An additional HK$4.00 million (7.50%) is earmarked for business development activities, while another HK$4.00 million (7.50%) is reserved for general corporate and working capital purposes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02257","symbol_name":"圣诺医药-B","start_time":0,"source_url":"","article_id":"1158230419","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158230419","pubTimestamp":1772965462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sirnaomics Ltd. reported that on March 7, 2026, 2.50 million new shares were issued at HK$12.00 each under Subscription Agreement A, resulting in a partial completion of the transaction. By mutual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02257":"圣诺医药-B"},"translate_title":"圣诺-B（股份代号：02257）宣布部分完成认购及终止剩馀股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02257":1},"content_text":"Sirnaomics Ltd. reported that on March 7, 2026, 2.50 million new shares were issued at HK$12.00 each under Subscription Agreement A, resulting in a partial completion of the transaction. By mutual agreement on the same date, the subscription for the remaining 9.07 million shares was terminated without further obligations.\nAfter this partial completion, the total number of shares increased from 107.22 million to 109.72 million. Following the issuance, the stake of the largest shareholder, Quarmaceutical Limited (wholly owned by Chairman and Executive Director Dr. Poon Hung Fai), changed from 16.44% to 16.07%. The shareholding of Dr. Yang Lu decreased from 5.02% to 4.90%, while Subscriber A owned 2.28% after the transaction.\nGross proceeds from the subscriptions amounted to HK$54.70 million, with net proceeds of HK$53.10 million. Of those net proceeds, HK$25.00 million (47.10%) is allocated to the development and commercialization of STP705, HK$3.50 million (6.60%) to STP122G, and HK$16.60 million (31.30%) to other drug candidates including STP707, STP125G, and STP144G. An additional HK$4.00 million (7.50%) is earmarked for business development activities, while another HK$4.00 million (7.50%) is reserved for general corporate and working capital purposes.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158230419","isCrawlerRequest":true}